PTAB deals Bass another blow
21-10-2015
Bass set for first IPR trial as Shire petition proceeds
09-10-2015
St22 / Shutterstock.com
Hedge fund manager Kyle Bass and his Coalition for Affordable Drugs have tasted success at the Patent Trial and Appeal Board (PTAB) for the second time in a month after it agreed to institute an inter partes review (IPR) of a patent covering a drug owned by NPS Pharmaceuticals.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
Register here for free content, or subscribe for access to archive.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
Kyle Bass; Coalition for Affordable Drugs; IPR; PTAB; USPTO; patents; Gattex; NPS Pharmaceuticals
